|
|
|
|
For patients with NVAF and additional risk factors for stroke,warfarin therapy led to a greater quality-adjusted survival and to cost savings.For patients with NVAF and one additional risk factor,warfarin therapy cost$ 8000 per quality-adjusted life-year saved.For 65-year-old patients with NVAF alone,warfarin cost about$370000 per quality-adjusted life-year saved,as compared with aspirin therapy.However,for 75-year-old patients with NVAF alone,prescribing warfarin cost$110000 per quality-adjusted life-year saved.For patients who were not prescribed warfarin,aspirin was preferred to no therapy on the basis of both quality-adjusted survival and cost in all patients,regardless of the number of risk factors present. Treatment with warfarin is cost-effective in patients with NVAF and one or more additional risk factors for stroke,prescribing warfarin instead of aspirin would affect quality-adjusted survival minimally but increase costs significantly. |
|